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Background: At present, cancer has become the leading threat to the health of
mankind. The lung cancer is one of the most common malignant tumors
worldwide. For the hidden symptoms and high malignant of initial lung cancer, it is
always late when the disease is diagnosed and the morbidity and mortality rates
are always at the top. Despite of continuous development of surgery and
chemical drugs, the treatment outcome is not satisfied. Early diagnosis and timely
treatment become the key to prevent the human’s health from lung cancer. With
the development of molecular biology, tumor-associated antigen (TAA) has been
gradually becoming the hot spot of modern medical attention. Not only could
patients be diagnosed in the early stage, but also the TAA can provide the basis
of tumor targeted therapy. Insulin -like growth factor 2 mRNA binding protein 2
(IGF2BP2) is a kind of cytoplasmic protein, which has been proved having a tight
connection with many tumors, such as hepatocellular carcinoma, breast cancer,
glioma, esophageal carcinoma, etc. But the relationship of IGF2BP2 and lung
cancer is still not clear.
Objective: This experiment aims to test the expression level of IGF2BP2 in the
lung cancer tissues and study the effects of IGF2BP2 on the biological behavior
on lung cancer cells. So that we can explore the association of IGF2BP2 and lung
cancer, and to clarify the IGF2BP2’s effects on the lung cancer.
Methods: We explored and analyzed the IGF2BP2 expression and its clinical
value through the organization and cell level. Firstly, we collect the lung cancer
tissue samples, from which we extracted the total proteins and RNAs. Then we
made an analysis through the Western Blot, RT-PCR technology. On the other
hand, we explored the influence of expression difference on the biological
characteristics of IGF2BP2, using the Western Blot, RT-PCR and cell transfection













Results: The result shows that the IGF2BP2 in cancer tissues expresses
significantly more than that in para-carcinoma tissues(P0.05). The IGF2BP2 in
cancer cells expresses significantly more than that in normal lung cells (P<0.01).
Knocking out the IGF2BP2 gene in lung cancer cells could reduce the ability of
cell proliferation and migration (P < 0.01)
Conclusion: IGF2BP2 contributes to proliferation and invasion of the lung cancer
cells, and plays an important role in the development of lung cancer, which
establishes the scientific basic for the clinical early diagnosis and prognosis of
lung cancer.
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